BFRA - Biofrontera's New Deal And Other News: The Good Bad And Ugly Of Biopharma
Biofrontera Inks New Licensing Deal, Reports FY 2019 Numbers
Biofrontera AG (BFRA) announced inking a new exclusive licensing deal with Maruho Co. Ltd. of Osaka, Japan. The deal pertains to the development and commercialization of Ameluz in East Asia and Oceania. Under the terms of the contract, Maruho will have exclusive development and commercialization rights, such as the right to sublicense the drug in certain geographies. Maruho will also retain the right to proceed with its own research and development within the bounds of the license.
The deal provides for an upfront payment